Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, Jiangsu, China.
Am J Cardiovasc Drugs. 2022 Nov;22(6):601-613. doi: 10.1007/s40256-022-00545-6. Epub 2022 Aug 10.
Among all of the new antidiabetic drugs, an increasing number of studies have evaluated the relationship between the sodium-glucose cotransporter 2 inhibitors (SGLT2i) and acute myocardial infarction (AMI). Since SGLT2i like empagliflozin, canagliflozin, and recently, dapagliflozin have shown impressive positive effects in patients with chronic heart failure with reduced ejection fraction (HFrEF), it has increased research interest to explore the cardiac molecular mechanisms underlying the clinical benefits and attracted more attention to the effects of SGLT2i on a series of cardiovascular events. Experimental and clinical data on SGLT2i treatment after AMI is limited. This is a review of the clinical and preclinical effects of SGLT2i, focusing on available data on the effects of SGLT2i in AMI patients with a brief overview of ongoing trials.
在所有新型抗糖尿病药物中，越来越多的研究评估了钠-葡萄糖共转运蛋白 2 抑制剂（SGLT2i）与急性心肌梗死（AMI）之间的关系。由于恩格列净、卡格列净和最近的达格列净在射血分数降低的慢性心力衰竭（HFrEF）患者中显示出令人印象深刻的积极效果，因此探索 SGLT2i 发挥临床获益的心脏分子机制的研究兴趣增加，并引起了更多对 SGLT2i 对一系列心血管事件影响的关注。关于 AMI 后 SGLT2i 治疗的实验和临床数据有限。这是对 SGLT2i 的临床和临床前作用的综述，重点介绍了 SGLT2i 在 AMI 患者中的作用的现有数据，并简要概述了正在进行的试验。
